Jacquie Ross | Vice President Investor Relations |
Daniel O’day | Chairman and Chief Executive Officer |
Johanna Mercier | Chief Commercial Officer |
Merdad Parsey | Chief Medical Officer |
Andrew Dickinson | Chief Financial Officer |
Matthew Harrison | Morgan Stanley |
Tyler Van Buren | Cowen |
Umer Raffat | Evercore |
Brian Abrahams | RBC Capital Markets |
Geoff Meacham | Bank of America |
Michael Yee | Jefferies |
Cory Kasimov | JPMorgan |
Andrew Garlow | Wolfe Research |
Geoffrey Porges | SVB Leerink |
Robyn Karnauskas | Unidentified |
Ronny Gal | Bernstein |
Brian Skorney | Baird |
Carter Gould | Barclays |
To the significant reduction in the risk of hospitalizations after a three-day IV treatment of Veklury and the outpatient setting. In order to meet additional treatment needs, we also continued to advance our oral programs to develop a novel best-in-class therapy.
Turning to HIV performance, we saw positive gains in the treatment market for the second quarter in a row, and reported record revenue for Biktarvy.
While treatment prescription volumes remained below pre -pandemic levels, we maintained total U.S. and EU treatment market share and we grew Biktarvy share sequentially in both geographies.